Cyclerion Therapeutics (CYCN) Regains Nasdaq Compliance

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that it has received a formal notice from The Nasdaq Stock Market stating that Cyclerion has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2), and that Cyclerion is in compliance with all applicable listing standards.

On June 1, 2022, Cyclerion was notified by Nasdaq that it was not in compliance with the minimum bid price rule because its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive business days. In order to regain compliance with the Rule, the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. This requirement was met on May 30, 2023, the tenth consecutive trading day when the closing bid price of the Company's common stock was over $1.00. This matter is now closed.

Cyclerion’s stock will continue to be listed and traded on the Nasdaq Capital Market.

You May Also Be Interested In

• HII wins $336M Navy contract for CVN 82 aircraft carrier materials
• Ball Corporation to build new beverage can plant in Uttar Pradesh
• Zenas BioPharma (ZBIO) files for up to 7M share offering by selling stockholders